ALK and non-small cell lung carcinoma: For NSCLC patients without ALK rearrangement, ROS1 rearrangement, or sensitized EGFR mutations, immune checkpoint inhibitors (nivolumab, pembrolizumab, and atezolizumab) are the preferred choice for subsequent treatment of all histological subtypes because they have a higher survival rate, Longer response duration and less adverse events (AE) chemotherapy compared to cytotoxicity [6].